Biovian is delighted to announce the successful completion of a debt refinancing initiative and securing a new funding package with Eurazeo, a French investment company, to support GeneCity facility expansion. The package will be used to refinance existing debt and to finance investment in GeneCity. The new funding package is an important milestone in Biovian’s growth journey and will support Biovian in continuing its strong organic growth.
Biovian is pleased to report that the GeneCity facility expansion project is progressing as planned. The investment is a strategic move aimed at meeting the growing demand for high-quality biopharmaceutical manufacturing services and further solidifying Biovian’s position as a trusted partner in the biopharmaceutical industry. The new viral vector facility building has been started in Q3/2023 and facility is expected to be ready in 2025.
A heartfelt thank you to our dedicated team, visionary investors, and esteemed partners. This support fuels our passion for innovation and propels us toward a future where genetic therapies revolutionize healthcare.
Biovian announces successful refinancing to support GeneCity facility expansionDownload